California State Teachers Retirement System (CalSTRS)’s ArriVent BioPharma AVBP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$931K Buy
26,798
+7,431
+38% +$219K ﹤0.01% 1966
2026
Q1
$447K Sell
19,367
-2,314
-11% -$52.3K ﹤0.01% 2104
2025
Q4
$436K Buy
21,681
+3,120
+17% +$64.9K ﹤0.01% 2143
2025
Q3
$342K Buy
18,561
+5,539
+43% +$109K ﹤0.01% 2189
2025
Q2
$283K Sell
13,022
-627
-5% -$13K ﹤0.01% 2214
2025
Q1
$252K Hold
13,649
– – ﹤0.01% 2262
2024
Q4
$364K Buy
13,649
+11,585
+561% +$333K ﹤0.01% 2241
2024
Q3
$48.5K Buy
2,064
+1,353
+190% +$30.7K ﹤0.01% 2431
2024
Q2
$13.2K Sell
711
-278
-28% -$4.96K ﹤0.01% 2777
2024
Q1
$17.7K Buy
+989
New +$19.9K ﹤0.01% 2771

Other funds holding AVBP

California State Teachers Retirement System (CalSTRS)'s AVBP Position: Q2 2026 in Review

California State Teachers Retirement System (CalSTRS) increased its ArriVent BioPharma (AVBP) stake by 38% in Q2 2026, buying an estimated $219K and bringing the position to 26,798 shares worth $931K. The position accounts for ﹤0.01% of the portfolio, ranked #1966.

California State Teachers Retirement System (CalSTRS) first reported a position in AVBP in Q1 2024 and has held it in 10 quarters since. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • California State Teachers Retirement System (CalSTRS) held 26,798 shares of ArriVent BioPharma worth $931K as of Q2 2026.
  • California State Teachers Retirement System (CalSTRS) bought 7,431 ArriVent BioPharma shares in Q2 2026, an estimated $219K.
  • ArriVent BioPharma made up ﹤0.01% of California State Teachers Retirement System (CalSTRS)'s portfolio in Q2 2026, its #1966 holding.
  • California State Teachers Retirement System (CalSTRS) first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 10 quarters since.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on California State Teachers Retirement System (CalSTRS)'s 13F filing for Q2 2026, filed 24 Aug 2026.